GSK: positive results for ViiV dual therapy
(CercleFinance.com) - On Thursday, ViiV Healthcare, a GSK subsidiary, unveiled the results of a "positive" phase III clinical study of a new class of HIV drug.
ViiV reported that its dual therapy of cabotegravir and rilpivirine (Janssen), injectable once every two months to treat HIV-1, has been as effective as a monthly injection over 48 weeks.
The once-a-month injectable dual therapy based on cabotegravir and rilpivirine to treat HIV-1 in adults with virological suppression is subject to a priority review by the US FDA, with a decision due by the end of the year.
Copyright (c) 2019 CercleFinance.com. All rights reserved.